

P19850.A09

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1614

Examiner: UNKNOWN

**Applicant** 

: BANERJEE et al.

Appl. No.

: 09/779,447

Filed

: February 9, 2001

For

: METHODS FOR INHIBITING ANGIOGENESIS

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

Further to the Information Disclosure Statement filed July 16, 2001, and pursuant to the duty of disclosure set forth in 37 C.F.R. 1.56, and in accordance with the provisions of 37 C.F.R. 1.97 and 1.98, the following information, which is cited and discussed in the present application, is brought to the attention of the Examiner:

DVORAK et al., <u>The New England Journal of Medicine</u>, Vol. 315, No. 26, pp. 1650-1659 (1986) is cited and discussed in the specification beginning at page 6;

BAIRD et al., <u>Biochemical and Biophysical Research Communications</u>, Vol. 126, No. 1, pp. 358-364 (1985) is cited and discussed in the specification beginning at page 6;

LEIBOVICH et al., <u>NATURE</u>, Vol. 329, pp. 630-632 (1987) is cited and discussed in the specification beginning at page 6;



FOLKMAN et al., <u>American Journal of Pathology</u>, Vol. 130, No. 2, pp. 393-400 (1988) is cited and discussed in the specification beginning at page 7;

SMOLIN et al., <u>American Journal of Ophthalmology</u>, pp. 147-151 (1971) is cited and discussed in the specification beginning at page 7;

LANIADO-SCHWARTZMAN et al., <u>The Journal of Biological Chemistry</u>, Vol. 269, No. 39, pp. 24321-24327 (1994) is cited and discussed in the specification beginning at page 10;

CARLBERG et al., <u>Carcinogenesis</u>, Vol. 17, No. 12, pp. 2589-2596 (1996) is cited and discussed in the specification beginning at page 20;

CHAPMAN et al., <u>Ann. Rev. Cell Dev. Biol.</u>, 14, pp. 459-485 (1998) is cited and discussed in the specification beginning at page 24;

CAI et al., <u>Journal of Cellular Physiology</u>, 177, pp. 282-288 (1998) is cited and discussed in the specification beginning at page 25;

Copies of the above-noted documents are enclosed. Each document is listed on the attached PTO-1449 form to permit the Examiner to indicate consideration thereof.

The Examiner is respectfully requested to consider the documents cited above and to confirm such consideration by initialling in the appropriate spaces on the PTO-1449 form and returning a copy of the initialled form to Applicants. It is also requested that these documents be identified in the list of references cited on the patent issuing for this application.

Applicants note that an Office Action on the Merits has not issued in the instant application. However, if an Office Action on the Merits has issued, and is crossing this statement in the mail, the



undersigned hereby authorizes the Commissioner to charge any fee necessary for consideration of this statement, including any payment under 37 C.F.R. 1.17(p), to be charged to Applicants' Deposit Account No. 19-0089.

The disclosure of the above documents does not constitute an admission that any particular document is relevant or material to the claims, or is prior analogous art with respect to the present application. The citation of these documents is not to be construed as a representation that no better art exists, or that a search has been made.

Any comments or questions concerning this application can be directed to the undersigned at the telephone number given below.

Respectfully submitted,

D. BANERJEE et al.

Arnold Turk Reg. No. 33,094

October 3, 2001 GREENBLUM & BERNSTEIN, P.L.C. 1941 Roland Clarke Place Reston, VA 20191 (703) 716-1191